What started as a simple consumer complaint has blossomed into a shining moment for the community. Abby Kreger has gone viral for "calling out" for not including cheese packets in four boxes of . In three TikTok videos, which had drawn more than 3.1 million views by Friday evening, the 29-year-old Kreger shared that she continued to bring home macaroni and cheese boxes that didn't have any sauce packets even after she connected with Kraft's costumer support team and got free coupons for future purchases. Kreger, who is the director of Pet Angel Adoption & Rescue in Frankenmuth, Michigan, was diagnosed with celiac disease about five years ago. Celiac is a chronic autoimmune disorder that damages the body's small intestines and prevents the body from absorbing nutrients from food. Individuals with celiac cannot eat gluten because their immune system attacks gluten as if it were a threat to the body, according to the . A few months after receiving her diagnosis, Kraft released its Gluten Free Original Mac & Cheese, which quickly became a "staple" in Kreger's diet. Well, until recently. Unknowingly, Kreger's world began to change on Oct. 1, when she opened two boxes of Kraft Gluten Free Original Mac & Cheese and neither had cheese sauce packets. Kreger contacted The Kraft Heinz Company's customer support, submitting photos of the boxes and providing necessary product information. Not long after, she received two coupons in the mail for two free boxes of the gluten-free macaroni and cheese. Kreger redeemed one of the coupons on Nov. 12, but when she opened the box back home, there was no cheese sauce packet. She contacted customer support again and was sent another coupon. On Monday, Kreger redeemed her latest coupon and like clockwork − no sauce. "I was like, 'This is ridiculous. Am I cursed?'" Kreger told USA TODAY in an interview. Kreger decided to turn to TikTok to share her story, hoping a "higher up" at Kraft would take notice. "I was thinking maybe like, 1,500 views because if you look at my videos, that's typically where my cat rescue videos sit around," Kreger said. As of Friday evening, the had 2 million views and Kreger's TikTok had 320,000 followers. Kreger said she was surprised at how positive the majority of the comments on the video are, with many TikTok users claiming they too had similar experiences with the gluten-free macaroni and cheese. In response to Kreger's , commented, "Hello. We apologize for this issue. We're not having any quality issues with our gluten-free Kraft Mac and Cheese." Kreger was surprised by the comment, but her followers didn't hesitate to let Kraft know how they felt. As of Friday evening, the three most recently posted videos on the feature comments referencing Kreger's video. In response to Kraft's comment, Kreger posted another video on Thursday, sharing more details about her correspondence with Kraft. Shortly after posting the second video in the mac and cheese saga, Kreger received a call from an "executive" with The Kraft Heinz Company who told her the company was investigating the issue and she should expect free goodies soon. In a statement provided to USA TODAY, a Kraft Mac & Cheese spokesperson said the company has been in touch with Kreger to apologize and "make things right." "We are working closely with our response teams to ensure all future inquiries are treated with the care and respect they deserve," the spokesperson said. "Our Quality Assurance team is also diligently investigating the production issue to determine the root cause and to fix it." With hopes to show Kreger they can do better, several companies have reached out to her, offering to send free gluten-free products. As of Friday evening, she had received gluten-free products from Stouffer's, California Pizza Kitchen and Instacart. Kreger told USA TODAY that she has also been in contact with companies like Banza, Annie's Homegrown, Craftmix and Texas-based Roni's Mac Bar, which has pledged to donate to Pet Angel Adoption & Rescue. Kreger said the free products have been "so unnecessary" and not what she had hoped for when reaching out to company initially. She just wanted the cheese packets. "Something in my heart kind of broke on the day I was diagnosed (with celiac) and how much support and overwhelming love and kindness that has happened through all of this has truly healed that part of my heart," Kreger said.Shopping on Temu can feel like playing an arcade game. Instead of using a joystick-controlled claw to grab a toy, visitors to the online marketplace maneuver their computer mouses or cellphone screens to browse colorful gadgets, accessories and trinkets with prices that look too good to refuse. A pop-up spinning wheel offers the chance to win a coupon. Rotating captions warn that a less than $2 camouflage print balaclava and a $1.23 skeleton hand back scratcher are “Almost sold out.” A flame symbol indicates a $9.69 plush cat print hoodie is selling fast. A timed-down selection of discounted items adds to the sense of urgency. Pages from the Shein website, left, and from the Temu site, right. Welcome to the new online world of impulse buying, a place of guilty pleasures where the selection is vast, every day is Cyber Monday, and an instant dopamine hit is always just a click away. By all accounts, we’re living in an accelerating age for consumerism, one that Temu, which is owned by the Chinese e-commerce company PDD Holdings, and Shein, its fierce rival , supercharged with social media savvy and an interminable assortment of cheap goods, most shipped directly from merchants in China based on real-time demand. The business models of the two platforms, coupled with avalanches of digital or influencer advertising, have enabled them to give Western retailers a run for their money this holiday shopping season. A Christmas tree ornament purchased on Temu. Software company Salesforce said it expects roughly one in five online purchases in the U.S., the United Kingdom, Australia and Canada to be made through four online marketplaces based or founded in Asia: Shein, Temu, TikTok Shop — the e-commerce arm of video-sharing platform TikTok — and AliExpress. Analysts with Salesforce said they are expected to pull in roughly $160 billion in global sales outside of China. Most of the sales will go to Temu and Shein, a privately held company which is thought to lead the worldwide fast fashion market in revenue. Lisa Xiaoli Neville, a nonprofit manager who lives in Los Angeles, is sold on Shein. The bedroom of her home is stocked with jeans, shoes, press-on nails and other items from the ultra-fast fashion retailer, all of which she amassed after getting on the platform to buy a $2 pair of earrings she saw in a Facebook ad. Neville, 46, estimates she spends at least $75 a month on products from Shein. A $2 eggshell opener, a portable apple peeler and an apple corer, both costing less than $5, are among the quirky, single-use kitchen tools taking up drawer space. She acknowledges she doesn’t need them because she “doesn’t even cook like that.” Plus, she’s allergic to apples. “I won’t eat apples. It will kill me,” Neville said, laughing. “But I still want the coring thing.” Shein, now based in Singapore, uses some of the same web design features as Temu’s, such as pop-up coupons and ads, to persuade shoppers to keep clicking, but it appears a bit more restrained in its approach. Shein primarily targets young women through partnerships with social media influencers. Searching the company's name on video platforms turns up creators promoting Shein's Black Friday sales event and displaying the dozens of of trendy clothes and accessories they got for comparatively little money. But the Shein-focused content also includes videos of TikTokers saying they're embarrassed to admit they shopped there and critics lashing out at fans for not taking into account the environmental harms or potential labor abuses associated with products that are churned out and shipped worldwide at a speedy pace. Neville has already picked out holiday gifts for family and friends from the site. Most of the products in her online cart cost under $10, including graphic T-shirts she intends to buy for her son and jeans and loafers for her daughter. All told, she plans to spend about $200 on gifts, significantly less than $500 she used to shell out at other stores in prior years. “The visuals just make you want to spend more money,” she said, referring to the clothes on Shein's site. “They're very cheap and everything is just so cute.” Unlike Shein, Temu's appeal cuts across age groups and gender. The platform is the world’s second most-visited online shopping site, software company Similarweb reported in September. Customers go there looking for practical items like doormats and silly products like a whiskey flask shaped like a vintage cellphone from the 1990s. Temu advertised Black Friday bargains for some items at upwards of 70% off the recommended retail price. Making a purchase can quickly result in receiving dozens of emails offering free giveaways. The caveat: customers have to buy more products. Despite their rise, Temu and Shein have proven particularly ripe for pushback. Last year, a coalition of unnamed brands and organizations launched a campaign to oppose Shein in Washington. U.S. lawmakers also have raised the possibility that Temu is allowing goods made with forced labor to enter the country. More recently, the Biden administration put forward rules that would crack down on a trade rule known as the de minimis exception, which has allowed a lot of cheap products to come into the U.S. duty-free. President-elect Donald Trump is expected to slap high tariffs on goods from China, a move that would likely raise prices across the retail world. Both Shein and Temu have set up warehouses in the U.S. to speed up delivery times and help them better compete with Amazon, which is trying to erode their price advantage through a new storefront that also ships products directly from China. Get the latest local business news delivered FREE to your inbox weekly.
Canada's top military commander calls out US senator for questioning a woman's role in combat
ITV I'm A Celebrity star left with plastic nose after brutal injury
NoneHypoxic Ischemic Encephalopathy Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Xenon Pharmaceuticals Inc., Amzell, Axcella Health, Rebiotix, Vedanta 11-22-2024 09:29 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoxic Ischemic Encephalopathy pipeline constitutes key companies continuously working towards developing Hypoxic Ischemic Encephalopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Hypoxic Ischemic Encephalopathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoxic Ischemic Encephalopathy Market. The Hypoxic Ischemic Encephalopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Hypoxic Ischemic Encephalopathy Pipeline Report: https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-hie-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Hypoxic Ischemic Encephalopathy treatment therapies with a considerable amount of success over the years. •Hypoxic Ischemic Encephalopathy companies working in the treatment market are CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, Axcella Health, Rebiotix, Stoke Therapeutics, Longboard Pharma, Knopp Bioscience, and others, are developing therapies for the Hypoxic Ischemic Encephalopathy treatment •Emerging Hypoxic Ischemic Encephalopathy therapies in the different phases of clinical trials are- MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, AXA 1665, RBX 7455, STK-001, LP352, KB-3061, and others are expected to have a significant impact on the Hypoxic Ischemic Encephalopathy market in the coming years. •In February 2024, ReAlta Life Sciences has initiated a Phase II clinical trial for its investigational drug RLS-0071, with the first subject enrolled to treat acute exacerbations of chronic obstructive pulmonary disease (AE-COPD). Additionally, the company has dosed the first patient in a separate Phase II trial of RLS-0071 targeting neonates with hypoxic-ischemic encephalopathy (HIE). •In August 2023, In a Phase II clinical trial using the medicine RLS-0071 to treat newborns with hypoxic-ischemic Hypoxic Ischemic Encephalopathy (HIE), also known as birth asphyxia, ReAlta Life Sciences has dosed the first patient. Hypoxic Ischemic Encephalopathy Overview Hypoxic Ischemic Encephalopathy (HIE) is a serious brain injury caused by a lack of oxygen (hypoxia) and blood flow (ischemia) to the brain. It commonly occurs during birth, particularly in newborns, and can result from complications such as umbilical cord issues, placental problems, or prolonged labor. HIE can lead to brain cell damage and varying degrees of neurological impairment, depending on the severity and duration of the oxygen deprivation. Symptoms may include seizures, muscle weakness, developmental delays, and cognitive impairments. Early intervention, such as therapeutic hypothermia, may help reduce brain damage and improve outcomes for affected individuals. Get a Free Sample PDF Report to know more about Hypoxic Ischemic Encephalopathy Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/hypoxic-ischemic-encephalopathy-hie-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Hypoxic Ischemic Encephalopathy Drugs Under Different Phases of Clinical Development Include: •MP-SCN: CAMP4 Therapeutics •SP-SCN8: LifeSplice •ETX101: Encoded Therapeutics •NRP 2945: CuroNZ •Tricaprilin: Cerecin •LP352: Longboard Pharmaceuticals •NBI-921352: Neurocrine Biosciences •VE303: Vedanta Biosciences •Vatiquinone: PTC Therapeutics •XEN496: Xenon Pharmaceuticals Inc. •AMZ 002: Amzell •AXA 1665: Axcella Health •RBX 7455: Rebiotix •STK-001: Stoke Therapeutics •LP352: Longboard Pharma •KB-3061: Knopp Bioscience Hypoxic Ischemic Encephalopathy Molecule Type Hypoxic Ischemic Encephalopathy Products have been categorized under various Molecule types, such as •Oligonucleotide •Peptide •Small molecule Hypoxic Ischemic Encephalopathy Pipeline Therapeutics Assessment •Hypoxic Ischemic Encephalopathy Assessment by Product Type •Hypoxic Ischemic Encephalopathy By Stage and Product Type •Hypoxic Ischemic Encephalopathy Assessment by Route of Administration •Hypoxic Ischemic Encephalopathy By Stage and Route of Administration •Hypoxic Ischemic Encephalopathy Assessment by Molecule Type •Hypoxic Ischemic Encephalopathy by Stage and Molecule Type DelveInsight's Hypoxic Ischemic Encephalopathy Report covers around products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Hypoxic Ischemic Encephalopathy product details are provided in the report. Download the Hypoxic Ischemic Encephalopathy pipeline report to learn more about the emerging Hypoxic Ischemic Encephalopathy therapies https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-hie-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Hypoxic Ischemic Encephalopathy Therapeutics Market include: Key companies developing therapies for Hypoxic Ischemic Encephalopathy are - Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences, and others. Hypoxic Ischemic Encephalopathy Pipeline Analysis: The Hypoxic Ischemic Encephalopathy pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Hypoxic Ischemic Encephalopathy with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoxic Ischemic Encephalopathy Treatment. •Hypoxic Ischemic Encephalopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Hypoxic Ischemic Encephalopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoxic Ischemic Encephalopathy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Hypoxic Ischemic Encephalopathy drugs and therapies https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-hie-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Hypoxic Ischemic Encephalopathy Pipeline Market Drivers •Increasing research & Development activities, continuous development of technology offering therapies for the treatment of various complications are some of the important factors that are fueling the Hypoxic Ischemic Encephalopathy Market. Hypoxic Ischemic Encephalopathy Pipeline Market Barriers •However, high cost of treatment, poor diagnosis in terms of the type of Hypoxic Ischemic Encephalopathy and other factors are creating obstacles in the Hypoxic Ischemic Encephalopathy Market growth. Scope of Hypoxic Ischemic Encephalopathy Pipeline Drug Insight •Coverage: Global •Key Hypoxic Ischemic Encephalopathy Companies: CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, Axcella Health, Rebiotix, Stoke Therapeutics, Longboard Pharma, Knopp Bioscience, and others •Key Hypoxic Ischemic Encephalopathy Therapies: MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, AXA 1665, RBX 7455, STK-001, LP352, KB-3061, and others •Hypoxic Ischemic Encephalopathy Therapeutic Assessment: Hypoxic Ischemic Encephalopathy current marketed and Hypoxic Ischemic Encephalopathy emerging therapies •Hypoxic Ischemic Encephalopathy Market Dynamics: Hypoxic Ischemic Encephalopathy market drivers and Hypoxic Ischemic Encephalopathy market barriers Request for Sample PDF Report for Hypoxic Ischemic Encephalopathy Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-hie-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Hypoxic Ischemic Encephalopathy Report Introduction 2. Hypoxic Ischemic Encephalopathy Executive Summary 3. Hypoxic Ischemic Encephalopathy Overview 4. Hypoxic Ischemic Encephalopathy- Analytical Perspective In-depth Commercial Assessment 5. Hypoxic Ischemic Encephalopathy Pipeline Therapeutics 6. Hypoxic Ischemic Encephalopathy Late Stage Products (Phase II/III) 7. Hypoxic Ischemic Encephalopathy Mid Stage Products (Phase II) 8. Hypoxic Ischemic Encephalopathy Early Stage Products (Phase I) 9. Hypoxic Ischemic Encephalopathy Preclinical Stage Products 10. Hypoxic Ischemic Encephalopathy Therapeutics Assessment 11. Hypoxic Ischemic Encephalopathy Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Hypoxic Ischemic Encephalopathy Key Companies 14. Hypoxic Ischemic Encephalopathy Key Products 15. Hypoxic Ischemic Encephalopathy Unmet Needs 16 . Hypoxic Ischemic Encephalopathy Market Drivers and Barriers 17. Hypoxic Ischemic Encephalopathy Future Perspectives and Conclusion 18. Hypoxic Ischemic Encephalopathy Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Hypoxic Ischemic Encephalopathy Market https://www.delveinsight.com/report-store/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hypoxic Ischemic Encephalopathy-Market Insights, Epidemiology, and Market Forecast-20324' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Hypoxic Ischemic Encephalopathy Epidemiology https://www.delveinsight.com/report-store/hypoxic-ischemic-encephalopathy-hie-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hypoxic Ischemic Encephalopathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market •Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market •Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market •Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market •Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market •Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market •Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market •Hemophilia A Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market •Herpes Simplex Virus Market: https://www.delveinsight.com/report-store/genital-herpes-market •Peripheral Nerve Injuries Market: https://www.delveinsight.com/infographics/peripheral-nerve-injuries-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.The Dallas Cowboys ruled out right guard Zack Martin and cornerback Trevon Diggs with injuries on Saturday, one day prior to a road game against the Washington Commanders. Martin has been dealing with ankle and shoulder injuries and didn't practice at all this week before initially being listed as doubtful to play on Friday. He also physically struggled during Monday night's loss to the Houston Texans. Martin, who turned 34 on Wednesday, has started all 162 games played in 11 seasons with the Cowboys. He's a nine-time Pro Bowl selection and a seven-time first-team All-Pro. Diggs has been dealing with groin and knee injuries. He was listed as questionable on Friday before being downgraded Saturday. Diggs, 26, has 37 tackles and two interceptions in 10 games this season. The two-time Pro Bowl pick led the NFL with 11 picks in 2021 and has 20 in 57 games. The Cowboys elected not to activate receiver Brandin Cooks (knee) for the game. He returned to practice earlier this week and he was listed as questionable on Friday. Dallas activated offensive tackle Chuma Edoga (toe) and defensive end Marshawn Kneeland (knee) off injured reserve Saturday, placed safety Markquese Bell (shoulder) on IR and released defensive end KJ Henry. Tight end Jake Ferguson (concussion) was previously ruled out. Tight end Princeton Fant was elevated from the practice squad to replace him. Cornerback Kemon Hall also was elevated from the practice squad. --Field Level MediaDA suggests unusual idea for halting Trump's hush money case while upholding conviction
Maximizing Fiber Infrastructure ROI Through Advanced Analytics: A Pioneer's Journey By Rajkumar KyadasuUCF, LSU face off with improved focus in mind
How to Master My “Line In the Sand” StrategyBillings police misconduct investigation leads to felony cases being dropped; hundreds of cases under review
Jaguar boss: I don’t care if Nigel Farage hates our car rebrandWhy is social media abuzz over Kraft's gluten-free mac & cheese? The mac mix-up explained.
Frequency Electronics Announces Second Quarter Fiscal 2025 Financial Results Conference Call: Tuesday, December 10, 2024, at 4:30 PM ET
None
Ration Card Canceled: Government canceled 5.8 crore ration cards, check your cardLangston Reynolds scores 31, Northern Colorado defeats Prairie View A&M 114-98
This Week in AI: AI Opens Door for Retailers to Gather Insights and Drive Spending
